182 related articles for article (PubMed ID: 10865204)
21. One year of alendronate treatment lowers microstructural stresses associated with trabecular microdamage initiation.
O'Neal JM; Diab T; Allen MR; Vidakovic B; Burr DB; Guldberg RE
Bone; 2010 Aug; 47(2):241-7. PubMed ID: 20483387
[TBL] [Abstract][Full Text] [Related]
22. Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra.
Komatsubara S; Mori S; Mashiba T; Ito M; Li J; Kaji Y; Akiyama T; Miyamoto K; Cao Y; Kawanishi J; Norimatsu H
J Bone Miner Res; 2003 Mar; 18(3):512-20. PubMed ID: 12619936
[TBL] [Abstract][Full Text] [Related]
23. Bisphosphonate treatment affects trabecular bone apparent modulus through micro-architecture rather than matrix properties.
Day JS; Ding M; Bednarz P; van der Linden JC; Mashiba T; Hirano T; Johnston CC; Burr DB; Hvid I; Sumner DR; Weinans H
J Orthop Res; 2004 May; 22(3):465-71. PubMed ID: 15099622
[TBL] [Abstract][Full Text] [Related]
24. Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage.
Li J; Mashiba T; Burr DB
Calcif Tissue Int; 2001 Nov; 69(5):281-6. PubMed ID: 11768198
[TBL] [Abstract][Full Text] [Related]
25. Treatment with eldecalcitol positively affects mineralization, microdamage, and collagen crosslinks in primate bone.
Saito M; Grynpas MD; Burr DB; Allen MR; Smith SY; Doyle N; Amizuka N; Hasegawa T; Kida Y; Marumo K; Saito H
Bone; 2015 Apr; 73():8-15. PubMed ID: 25482210
[TBL] [Abstract][Full Text] [Related]
26. The structural and biomechanical basis of the gain and loss of bone strength in women and men.
Seeman E
Endocrinol Metab Clin North Am; 2003 Mar; 32(1):25-38. PubMed ID: 12699291
[TBL] [Abstract][Full Text] [Related]
27. Remodeling and the repair of fatigue damage.
Burr DB
Calcif Tissue Int; 1993; 53 Suppl 1():S75-80; discussion S80-1. PubMed ID: 8275384
[TBL] [Abstract][Full Text] [Related]
28. Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dietary fluoride on biomechanical and morphological changes in chick bones.
Chan MM; Riggins RS; Rucker RB
J Nutr; 1977 Sep; 107(9):1747-54. PubMed ID: 408470
[TBL] [Abstract][Full Text] [Related]
29. Antiresorptive drugs and trabecular bone turnover: validation and testing of a computer model.
Lacy ME; Bevan JA; Boyce RW; Geddes AD
Calcif Tissue Int; 1994 Mar; 54(3):179-85. PubMed ID: 8055363
[TBL] [Abstract][Full Text] [Related]
30. Sodium etidronate in the treatment of Paget's disease of bone. A study of long-term results.
Khairi MR; Altman RD; DeRosa GP; Zimmermann J; Schenk RK; Johnston CC
Ann Intern Med; 1977 Dec; 87(6):656-63. PubMed ID: 412450
[TBL] [Abstract][Full Text] [Related]
31. A strategy for the management of elderly women with primary hyperparathyroidism: a comparison of etidronate therapy with parathyroidectomy.
Horiuchi T; Onouchi T; Inoue J; Shionoiri A; Hosoi T; Orimo H
Gerontology; 2002; 48(2):103-8. PubMed ID: 11867933
[TBL] [Abstract][Full Text] [Related]
32. High-dose risedronate treatment partially preserves cancellous bone mass and microarchitecture during long-term disuse.
Yang Li C; Majeska RJ; Laudier DM; Mann R; Schaffler MB
Bone; 2005 Sep; 37(3):287-95. PubMed ID: 16006205
[TBL] [Abstract][Full Text] [Related]
33. Effect of EHDP on fracture healing in dogs.
Lenehan TM; Balligand M; Nunamaker DM; Wood FE
J Orthop Res; 1985; 3(4):499-507. PubMed ID: 3934355
[TBL] [Abstract][Full Text] [Related]
34. Spontaneous fractures of uninvolved bones in patients with Paget's disease during unduly prolonged treatment with disodium etidronate (EHDP).
Mautalen C; Gonzalez D; Blumenfeld EL; Santini Araujo E; Schajowicz F
Clin Orthop Relat Res; 1986 Jun; (207):150-5. PubMed ID: 3087670
[TBL] [Abstract][Full Text] [Related]
35. Aging and matrix microdamage accumulation in human compact bone.
Schaffler MB; Choi K; Milgrom C
Bone; 1995 Dec; 17(6):521-25. PubMed ID: 8835305
[TBL] [Abstract][Full Text] [Related]
36. Bone microdamage: a clinical perspective.
Chapurlat RD; Delmas PD
Osteoporos Int; 2009 Aug; 20(8):1299-308. PubMed ID: 19291343
[TBL] [Abstract][Full Text] [Related]
37. Effect of ethane-1-hydroxy-1,1-diphosphonate on ectopic bone formation induced by murine osteosarcoma-derived bone-inducing substance.
Nakahara H; Yoshikawa H; Takaoka K; Ono K
Bone; 1986; 7(3):229-33. PubMed ID: 3094564
[TBL] [Abstract][Full Text] [Related]
38. Effects of risedronate in Runx2 overexpressing mice, an animal model for evaluation of treatment effects on bone quality and fractures.
Geoffroy V; Paschalis EP; Libouban H; Blouin S; Ostertag A; Chappard D; Cros M; Phipps R; de Vernejoul MC
Calcif Tissue Int; 2011 Jun; 88(6):464-75. PubMed ID: 21455736
[TBL] [Abstract][Full Text] [Related]
39. The effects of tensile-compressive loading mode and microarchitecture on microdamage in human vertebral cancellous bone.
Lambers FM; Bouman AR; Tkachenko EV; Keaveny TM; Hernandez CJ
J Biomech; 2014 Nov; 47(15):3605-12. PubMed ID: 25458150
[TBL] [Abstract][Full Text] [Related]
40. Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: what we think we know and what we know that we don't know.
Allen MR; Burr DB
Bone; 2011 Jul; 49(1):56-65. PubMed ID: 20955825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
